Phase 3 Readout~month
Phase 3 Topline: Apa/Enza Short Study: Shortened 12 Months Duration of Androgen Receptor Signaling Agent in Combinati
- Company
- KYNTRA BIO INC. (KYNB)
- Drug
- androgen
- Indication
- Prostate Cancer
Other upcoming events for KYNB
Phase 3 ReadoutPhase 3 Topline: An Open-Label, Multicenter Extension Study in Participants Previously Enrolled in a Genentech and/or
Phase 3 ReadoutPhase 3 Topline: ProBio: An Outcome-adaptive and Randomized Multi-arm Biomarker Driven Study in Patients With Metasta
Phase 3 ReadoutPhase 3 Topline: CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Double-Blind, Randomized, Two-Period, Multicenter, Placebo-Controlled, Efficacy and Safet
Phase 3 ReadoutPhase 3 Topline: An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F.
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.